Novo Nordisk experienced its worst day in history, with a loss of over 100 billion dollars in market value following a significant decline in Wegovy sales. Over one million Americans have turned to off-brand alternatives, causing profits to diminish rapidly and triggering numerous lawsuits. The company has cut its 2025 forecast again, raising concerns about whether this setback is temporary or signals a potential collapse of the weight loss drug industry. The situation has sent shockwaves through the market.